GlassScriptPhysician profile
Haley M Griggs
NPI 1669061271
$1,817.48
in general payments reported to CMS, 2019-2025
31 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,340 · 2022: $272 · 2023: $17.19 · 2024: $35.75 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.83 | 2021-2022 | |
| Novo Nordisk INC | $187.34 | 2021-2022 | |
| Amarin Pharma, INC. | $182.93 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $168.18 | 2021 | |
| Shockwave Medical, INC | $137.99 | 2025 | |
| Lilly USA, LLC | $134.62 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $114.92 | 2021-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $74.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $61.43 | 2021-2023 | |
| Esperion Therapeutics, INC. | $58.92 | 2021 | |
| Eisai INC. | $49.30 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $39.13 | 2021 | |
| Abbvie INC. | $39.04 | 2021 | |
| Jazz Pharmaceuticals INC. | $36.83 | 2021-2022 | |
| Boston Scientific Corporation | $35.75 | 2024 | Spectra Wavewriter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $28.99 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $26.16 | 2021 | |
| Dexcom, INC. | $18.72 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.17 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.93 | 2022 | |
| Adlon Therapeutics L.P. | $15.74 | 2021 | |
| Daiichi Sankyo INC. | $15.63 | 2021 | |
| Bausch Health US, LLC | $14.52 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.03 | 2021 | |
| Antares Pharma, INC. | $13.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 | |
| Merck Sharp & Dohme LLC | $11.95 | 2021 | |
| Astellas Pharma US INC | $11.72 | 2021 | |
| Genentech USA, INC. | $10.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Griggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.